TCRX - TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting | Benzinga
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of six abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 1-5, 2023, both in San Diego, CA and virtually.
Presentation Details:
Title: Product Characteristics and Clinical Trial Design for T-Plex, a Multiplexed, Enhanced T cell Receptor-Engineered T cell Therapy for Solid Tumors
Authors: Shrikanta Chattopadhyay, Antoine J Boudot, Ribhu Nayar, Hannah Bader, Andrew Ferretti, Tary Traore, Nancy Nabilsi, Jenny Tadros, Badr Kiaf, Yifan Wang, Victor Ospina, Alok Das Mahopatra, Zhonghua Zhu, Qikai Xu, Krista Daniels, Briana Zimmerman, Mollie Jurewicz, Amanda Kordosky, Chris Malcuit, Yun Wang, Marlyane Motta, Jim Murray, Ray Lockard, Cagan Gurer, Debora Barton, Gavin MacBeath
Abstract Number: 709
Date & Time: Friday, November 3, 2023, 9:00 a.m. – 7:00 p.m. PT
Location: Exhibit Halls A and B1 – San Diego Convention Center
Title: Discovery of a novel MAGEC2 epitope for TCR-T adoptive cell therapy from expanded T cell clones of TIL therapy products
Authors: Andrew Ferretti, Adam Weinheimer, Dalena Nguyen, Olivia Pryor, Sarah Bertino, Qikai Xu, Yifan Wang, Els M.E. Verdegaal, Sjoerd H. van der Burg, Cagan Gurer, Gavin MacBeath
Abstract Number: 357
Date & Time: Friday, November 3, 2023, 9:00 a.m. – 7:00 p.m. PT
Location: Exhibit Halls A and B1 – San Diego Convention Center
Title: Overcoming tumor heterogeneity – ...